Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Ars Technica ·
Markers released top-line results today after previously reporting the trial succeeded.
Publication and source information
- Platform
- NewsTiVi
- Source
- Ars Technica
- Published
- 10/22/2026, 10:12:19 PM
- Country
- United States
The headline and summary are supplied by the publisher. Read the full report on the source website.
Contact: info@newstivi.com